A.L. Jackman

ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.

A.L. Jackman, G A Taylor, William Gibson et al. · PubMed · 1991 · 359 citations

Pharmaceutical Science, Pharmacotherapy, Pharmaceutical Chemistry +20

Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines

A.L. Jackman, Rosemary Kimbell, Melody Brown et al. · British Journal of Cancer · 1995 · 102 citations · Full text

Natural Sciences, Molecular Biology, Resistance Mutation (Virology) +5

A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.

A H Calvert, D Alison, S. J. Harland et al. · Journal of Clinical Oncology · 1986 · 102 citations

Pathology, Pharmacotherapy, Pharmaceutical Chemistry +24

Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues.

S J Welsh, Jenny Titley, Lisa Brunton et al. · PubMed · 2000 · 75 citations

Immunology, Thymidylate Synthase, Immunotherapy +16

Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.

A.L. Jackman, G A Taylor, BM O'Connor et al. · PubMed · 1990 · 61 citations

Molecular Pharmacology, Medicinal Chemistry, Biosynthesis +14